FRANKLIN LAKES, N.J.,
April 8, 2019 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced the global availability
of BD BACTEC™ platelet quality control media, which allows
microbiology laboratories, blood banks and transfusion services to
identify contaminated platelet units.
An estimated 12 million apheresis platelet donations are
collected each year.1 Platelets are associated with a
higher risk of sepsis and related fatality than any other
transfusable blood component.2 The World Health
Organization (WHO), U.S. Food and Drug Administration (FDA) and
American Association of Blood Banks (AABB) have introduced
guidelines and protocols for the detection of bacterial
contamination in platelet donations, helping to reduce septic
transfusion reactions and related fatalities by an estimated 50 to
70 percent.3,4,5
"The availability of the BD BACTEC platelet quality control
media allows clinicians the opportunity to identify potentially
contaminated platelet donations by using a culture-based
methodology, helping to reduce the risk of sepsis," said
Gerald Denys, Ph.D., senior research
professor of pathology and laboratory medicine at Indiana University School of Medicine.
BD BACTEC™ platelet quality control media is part of a
comprehensive solution leveraging the automated BD BACTEC™ FX
technology and BD Synapsys™ microbiology informatics solution to
help laboratories meet culture-based platelet testing requirements.
The recent FDA 510(k) clearance of BD BACTEC™ platelet quality
control media adheres to FDA guidelines for culture-based methods
and meets requirements of the CE-IVD directive. The product can be
used for quality control testing of leukocyte reduced apheresis
platelet (LRAP) units, both leukocyte reduced single and a pool of
up to six units of leukocyte reduced whole blood platelet
concentrates (LRWBPC).
"The addition of BD BACTEC platelet quality control media builds
on our legacy of offering accurate and cost-effective solutions
through our BD BACTEC portfolio," said Steve Conly, vice president, general manager of
microbiology for BD. "By offering this FDA cleared product, we hope
to help our customers better serve some of their most vulnerable
patients while minimizing the health and financial burdens
associated with sepsis."
BD BACTEC™ platelet quality control media is now available
globally. Visit https://go.bd.com/Platelet-media.html for more
information.
About BD BACTEC™ Solutions
BD BACTEC™ blood culture system, offering a scalable footprint,
helps clinicians diagnose bloodstream infections with a range of
blood culture media and instrumentation. Coupled with a wide
variety of culture media formulations, BD provides screening for
microorganisms present in blood and blood components.
BD BACTEC™ FX instruments powered by BD Synapsys™ microbiology
informatics solution may enhance laboratory's ability to track
samples and report results with an intuitive, browser-based
interface.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of healthcare by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for
healthcare providers. BD and its 65,000 employees have a passion
and commitment to help enhance the safety and efficiency of
clinicians' care delivery process, enable laboratory scientists to
accurately detect disease and advance researchers' capabilities to
develop the next generation of diagnostics and therapeutics. BD has
a presence in virtually every country and partners with
organizations around the world to address some of the most
challenging global health issues. By working in close collaboration
with customers, BD can help enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to healthcare. In
2017, BD welcomed C. R. Bard and its products into the BD family.
For more information on BD, please visit
bd.com.
1. Global Status Report on Blood Safety and Availability Report,
World Health Organization, 2016.
2. Bacterial Risk Control Strategies for Blood Collection
Establishments and Transfusion Services to Enhance the Safety and
Availability of Platelets for Transfusion, March, 2016.
3. Blood Products Advisory Committee Meeting FDA White Oak Campus,
Silver Spring, MD July 18, 2018.
4. Fuller AK, Uglik KM, Savage WJ, Ness PM, King KE. Bacterial
culture reduces but does not eliminate the risk of septic
transfusion reactions to single-donor platelets. Transfusion.
2009;49(12):2588-2593.
5. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of
apheresis platelets and the residual risk of septic transfusion
reactions: the American Red Cross experience (2004-2006).
Transfusion. 2007;47(7):1134-1142.
Contacts:
|
|
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
gwen.gordon@bd.com
|
monique_dolecki@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-unveils-platelet-quality-control-media-to-help-reduce-the-incidence-of-sepsis-in-patients-requiring-platelet-transfusion-300825707.html
SOURCE BD (Becton, Dickinson and Company)